{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T17:29:29Z","timestamp":1747330169400},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,24]],"date-time":"2015-02-24T00:00:00Z","timestamp":1424736000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["19300254","22300264","25282029"],"award-info":[{"award-number":["19300254","22300264","25282029"]}]},{"DOI":"10.13039\/501100004043","name":"Kanazawa Medical University","doi-asserted-by":"publisher","award":["SR2012-04"],"award-info":[{"award-number":["SR2012-04"]}],"id":[{"id":"10.13039\/501100004043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"MEXT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["medical-hypotheses.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.mehy.2015.02.002","type":"journal-article","created":{"date-parts":[[2015,2,10]],"date-time":"2015-02-10T02:30:58Z","timestamp":1423535458000},"page":"490-493","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Serum levels of toxic AGEs (TAGE) may be a promising novel biomarker in development and progression of NASH"],"prefix":"10.1016","volume":"84","author":[{"given":"M.","family":"Takeuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Sakasai-Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Takata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Takino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Hyogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Yamagishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2015.02.002_b0005","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.22603","article-title":"Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management","volume":"49","author":"Vuppalanchi","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.mehy.2015.02.002_b0010","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1002\/hep.1840220616","article-title":"The natural history of nonalcoholic fatty liver: a follow-up study","volume":"22","author":"Teli","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.mehy.2015.02.002_b0015","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1136\/gut.2003.019984","article-title":"Long term prognosis of fatty liver: risk of chronic liver disease and death","volume":"53","author":"Dam-Larsen","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.mehy.2015.02.002_b0020","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0016-5085(99)70506-8","article-title":"Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity","volume":"116","author":"Matteoni","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mehy.2015.02.002_b0025","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1053\/jhep.2002.30692","article-title":"NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome","volume":"35","author":"Chitturi","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.mehy.2015.02.002_b0030","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.2337\/diabetes.50.8.1844","article-title":"Nonalcoholic fatty liver disease: a feature of the metabolic syndrome","volume":"50","author":"Marchesini","year":"2001","journal-title":"Diabetes"},{"key":"10.1016\/j.mehy.2015.02.002_b0035","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2174\/138161208784139701","article-title":"Advanced glycation end products (AGEs) and their involvement in liver disease","volume":"14","author":"Hyogo","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.mehy.2015.02.002_b0040","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MOG.0b013e3283358a58","article-title":"Implications of diet on nonalcoholic fatty liver disease","volume":"26","author":"Sullivan","year":"2010","journal-title":"Curr Opin Gastroenterol"},{"key":"10.1016\/j.mehy.2015.02.002_b0045","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jhep.2007.06.020","article-title":"Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study","volume":"47","author":"Zelber-Sagi","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.mehy.2015.02.002_b0050","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jhep.2008.02.011","article-title":"Fructose consumption as a risk factor for non-alcoholic fatty liver disease","volume":"48","author":"Ouyang","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.mehy.2015.02.002_b0055","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/hep.23535","article-title":"Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease","volume":"51","author":"Abdelmalek","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.mehy.2015.02.002_b0060","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1155\/2008\/810961","article-title":"Soft drink consumption linked with fatty liver in the absence of traditional risk factors","volume":"22","author":"Assy","year":"2008","journal-title":"Can J Gastroenterol"},{"key":"10.1016\/j.mehy.2015.02.002_b0065","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2009.05.033","article-title":"Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome","volume":"51","author":"Abid","year":"2009","journal-title":"J Hepatol"},{"issue":"Suppl.","key":"10.1016\/j.mehy.2015.02.002_b0070","doi-asserted-by":"crossref","first-page":"748S","DOI":"10.1093\/ajcn\/58.5.748S","article-title":"Fructose absorption","volume":"58","author":"Riby","year":"1993","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.mehy.2015.02.002_b0075","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0074-7742(02)50082-9","article-title":"Polyol pathway and diabetic peripheral neuropathy","volume":"50","author":"Oates","year":"2002","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.mehy.2015.02.002_b0080","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1254\/jjp.88.123","article-title":"Gene expression of enzymes comprising the polyol pathway in various rat tissues determined by the competitive RT-PCR method","volume":"88","author":"Maekawa","year":"2002","journal-title":"Jpn J Pharmacol"},{"key":"10.1016\/j.mehy.2015.02.002_b0085","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/dmrr.488","article-title":"Fructose-mediated non-enzymatic glycation: sweet coupling or bad modification","volume":"20","author":"Schalkwijk","year":"2004","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.mehy.2015.02.002_b0090","first-page":"294","article-title":"Adverse effects of dietary fructose","volume":"10","author":"Gaby","year":"2005","journal-title":"Altern Med Rev"},{"key":"10.1016\/j.mehy.2015.02.002_b0095","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.mehy.2004.03.005","article-title":"Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo","volume":"63","author":"Takeuchi","year":"2004","journal-title":"Med Hypotheses"},{"key":"10.1016\/j.mehy.2015.02.002_b0100","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3233\/JAD-2009-0974","article-title":"Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer\u2019s disease","volume":"16","author":"Takeuchi","year":"2009","journal-title":"J Alzheimer Dis"},{"key":"10.1016\/j.mehy.2015.02.002_b0105","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.2174\/1389450111009011468","article-title":"Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: a novel therapeutic strategy","volume":"11","author":"Takeuchi","year":"2010","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.mehy.2015.02.002_b0110","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1007\/s00125-006-0437-7","article-title":"Telmisartan inhibits AGE-induced C-reactive protein production through downregulation of the receptor for AGE via peroxisome proliferator-activated receptor-gamma activation","volume":"49","author":"Yoshida","year":"2006","journal-title":"Diabetologia"},{"key":"10.1016\/j.mehy.2015.02.002_b0115","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s00535-007-2152-7","article-title":"Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells","volume":"43","author":"Iwamoto","year":"2008","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.mehy.2015.02.002_b0120","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/j.1440-1746.2007.04943.x","article-title":"Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis","volume":"22","author":"Hyogo","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.mehy.2015.02.002_b0125","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s00535-010-0203-y","article-title":"Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH","volume":"45","author":"Kimura","year":"2010","journal-title":"J Gastroenterol"},{"issue":"Suppl. 1","key":"10.1016\/j.mehy.2015.02.002_b0130","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1053\/j.gastro.2004.09.011","article-title":"Primary liver cancer: worldwide incidence and trends","volume":"127","author":"Bosch","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mehy.2015.02.002_b0135","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.mehy.2015.02.002_b0140","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.21797","article-title":"Elevation of serum levels of advanced glycation end products in patients with non-B or non-C hepatocellular carcinoma","author":"Kan","year":"2014","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.mehy.2015.02.002_b0145","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/S0140-6736(99)00163-4","article-title":"Non-alcoholic steatohepatitis: another disease of affluence","volume":"353","author":"James","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2015.02.002_b0150","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u2018hits\u2019?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.mehy.2015.02.002_b0155","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s10238-006-0115-6","article-title":"Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes","volume":"6","author":"Jinnouchi","year":"2006","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.mehy.2015.02.002_b0160","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.taap.2010.11.011","article-title":"Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment","volume":"251","author":"Vil\u00e0","year":"2011","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.mehy.2015.02.002_b0165","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.3748\/wjg.v16.i42.5334","article-title":"MK615 decreases RAGE expression and inhibits TAGE-induced proliferation in hepatocellular carcinoma cells","volume":"16","author":"Sakuraoka","year":"2010","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.mehy.2015.02.002_b0170","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1007\/s00270-011-0293-9","article-title":"Serum gamma-glutamyl-transferase independently predicts outcome after transarterial chemoembolization of hepatocellular carcinoma: external validation","volume":"35","author":"Guiu","year":"2012","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.mehy.2015.02.002_b0175","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1097\/MEG.0b013e32834902dd","article-title":"Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization","volume":"23","author":"Zhang","year":"2011","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.mehy.2015.02.002_b0180","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00535-009-0050-x","article-title":"Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation","volume":"44","author":"Ju","year":"2009","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.mehy.2015.02.002_b0185","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-511X-5-4","article-title":"Influence of liver cancer on lipid and lipoprotein metabolism","volume":"5","author":"Jiang","year":"2006","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.mehy.2015.02.002_b0190","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2174\/156652406776894536","article-title":"TAGE (toxic AGEs) theory in diabetic complications","volume":"6","author":"Sato","year":"2006","journal-title":"Curr Mol Med"},{"key":"10.1016\/j.mehy.2015.02.002_b0195","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.2174\/13816128113199990476","article-title":"Nonalcoholic fatty liver disease and cardiovascular disease","volume":"20","author":"Hyogo","year":"2014","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.mehy.2015.02.002_b0200","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1007\/s00535-009-0193-9","article-title":"The formation of intracellular glyceraldehyde-derived advanced glycation end-products and cytotoxicity","volume":"45","author":"Takino","year":"2010","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.mehy.2015.02.002_b0205","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00401-004-0871-x","article-title":"Glyceraldehyde-derived advanced glycation end products in Alzheimer\u2019s disease","volume":"108","author":"Choei","year":"2004","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.mehy.2015.02.002_b0210","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1177\/1533317506289277","article-title":"Toxic advanced glycation end products (TAGE) theory in Alzheimer\u2019s disease","volume":"21","author":"Sato","year":"2006","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.1016\/j.mehy.2015.02.002_b0215","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2174\/138161208784139693","article-title":"Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer\u2019s disease","volume":"14","author":"Takeuchi","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.mehy.2015.02.002_b0220","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2174\/138161208784139765","article-title":"AGE-RAGE system and carcinogenesis","volume":"14","author":"Abe","year":"2008","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.mehy.2015.02.002_b0225","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.3748\/wjg.v18.i15.1781","article-title":"Glycer-AGEs-RAGE signaling enhances the angiogenic potential of hepatocellular carcinoma by upregulating VEGF expression","volume":"18","author":"Takino","year":"2012","journal-title":"World J Gastroenterol"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987715000699?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987715000699?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T16:14:44Z","timestamp":1566317684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987715000699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0306987715000699"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2015.02.002","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum levels of toxic AGEs (TAGE) may be a promising novel biomarker in development and progression of NASH","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2015.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}